keyword
MENU ▼
Read by QxMD icon Read
search

HIV, Hepatitis c

keyword
https://www.readbyqxmd.com/read/28434128/aspects-on-the-history-of-transmission-and-favor-of-distribution-of-viruses-by-iatrogenic-action-perhaps-an-example-of-a-paradigm-of-the-worldwide-spread-of-hiv
#1
REVIEW
Lutz G Gürtler, Josef Eberle
Transmission of infectious agents might be associated with iatrogenic actions of charitable help in health care. An example is the vaccination against yellow fever in USA that transmitted hepatitis B virus. Another example is injections of praziquantel for treatment and cure of schistosomiasis in Central and Northern Africa, with a focus in Egypt that has spread hepatitis C virus. There is no indication that human T-lymphotropic virus type 1 was spread by injection treatment for African trypanosomiasis, syphilis and treponematosis, but these treatments might have contributed to the early spread of human immunodeficiency virus type 1 (HIV-1) in Central Africa...
April 22, 2017: Medical Microbiology and Immunology
https://www.readbyqxmd.com/read/28432579/hcv-cure-and-reinfection-among-people-with-hiv-hcv-coinfection-and-people-who-inject-drugs
#2
REVIEW
Marianne Martinello, Behzad Hajarizadeh, Jason Grebely, Gregory J Dore, Gail V Matthews
PURPOSE OF REVIEW: Highly effective, well-tolerated interferon-free direct-acting antivirals (DAA) have revolutionised hepatitis C virus (HCV) therapeutics, with the opportunity for broad treatment scale-up among marginalised or "high-risk" populations, including people who inject drugs (PWID) and people with HIV/HCV coinfection. RECENT FINDINGS: Concern that HCV reinfection may compromise HCV treatment outcomes is sometimes cited as a reason for not offering treatment to current and former PWID...
April 21, 2017: Current HIV/AIDS Reports
https://www.readbyqxmd.com/read/28431845/infection-prevention-and-control-and-the-refugee-population-experiences-from-the-university-of-louisville-global-health-center
#3
Ruth M Carrico, Linda Goss, Timothy L Wiemken, Rahel S Bosson, Paula Peyrani, William A Mattingly, Allison Pauly, Rebecca A Ford, Stanley Kotey, Julio A Ramirez
BACKGROUND: During 2016, approximately 140,000 individuals entered the United States as part of the federal government refugee resettlement program and established themselves in communities in virtually every state. No national database regarding refugee health currently exists; therefore, little is known about existing infectious diseases, conditions, and cultural practices that impact successful acculturation. The objective of this report is to identify what is currently known about refugees and circumstances important to infection prevention and control with respect to their roles as new community members, employees, and consumers of health care...
April 18, 2017: American Journal of Infection Control
https://www.readbyqxmd.com/read/28431584/monitoring-quality-and-coverage-of-harm-reduction-services-for-people-who-use-drugs-a-consensus-study
#4
Lucas Wiessing, Marica Ferri, Vendula Běláčková, Patrizia Carrieri, Samuel R Friedman, Cinta Folch, Kate Dolan, Brian Galvin, Peter Vickerman, Jeffrey V Lazarus, Viktor Mravčík, Mirjam Kretzschmar, Vana Sypsa, Ana Sarasa-Renedo, Anneli Uusküla, Dimitrios Paraskevis, Luis Mendão, Diana Rossi, Nadine van Gelder, Luke Mitcheson, Letizia Paoli, Cristina Diaz Gomez, Maitena Milhet, Nicoleta Dascalu, Jonathan Knight, Gordon Hay, Eleni Kalamara, Roland Simon, Catherine Comiskey, Carla Rossi, Paul Griffiths
BACKGROUND AND AIMS: Despite advances in our knowledge of effective services for people who use drugs over the last decades globally, coverage remains poor in most countries, while quality is often unknown. This paper aims to discuss the historical development of successful epidemiological indicators and to present a framework for extending them with additional indicators of coverage and quality of harm reduction services, for monitoring and evaluation at international, national or subnational levels...
April 22, 2017: Harm Reduction Journal
https://www.readbyqxmd.com/read/28430385/significant-reductions-in-alcohol-use-after-hepatitis-c-treatment-results-from-the-french-anrs-co13-hepavih-cohort
#5
Rod Knight, Perrine Roux, Antoine Vilotitch, Fabienne Marcellin, Eric Rosenthal, Laure Esterle, François Boué, David Rey, Lionel Piroth, Stéphanie Dominguez, Philippe Sogni, Dominique Salmon-Ceron, Bruno Spire, Maria Patrizia Carrieri
BACKGROUND AND AIMS: Few data exist on changes to substance use patterns before and after hepatitis C virus (HCV) treatment. We used longitudinal data of HIV-HCV co-infected individuals to examine whether receiving Peg-interferon (Peg-IFN)-based therapy irrespective of HCV clearance could modify tobacco, cannabis and alcohol use. DESIGN: A prospective cohort of HIV-HCV co-infected individuals was enrolled from 2006. Participants' clinical data were retrieved from medical records and socio-demographic and behavioral characteristics were collected by yearly self-administered questionnaires...
April 21, 2017: Addiction
https://www.readbyqxmd.com/read/28426354/-it-goes-on-everywhere-injection-drug-use-in-canadian-federal-prisons
#6
Emily van der Meulen
BACKGROUND: International and Canadian research on in-prison injection drug use has documented the frequency of its occurrence as well as some of the resulting consequences such as increased prevalence of HIV and hepatitis C virus. Access to prison-based harm reduction programing is thus important. OBJECTIVES: The aim of this study was to learn from former prisoner experiences and insights on in-prison injection drug use in order to advance and improve access to harm reduction options, in particular prison-based needle and syringe programs (PNSPs)...
June 7, 2017: Substance Use & Misuse
https://www.readbyqxmd.com/read/28419653/hcv-viremia-associates-with-nk-cell-activation-and-dysfunction-in-anti-retroviral-hiv-hcv-co-infected-subjects
#7
E Papasavvas, L Azzoni, X Yin, Q Liu, J Joseph, A Mackiewicz, B Ross, K M Lynn, J M Jacobson, K Mounzer, J R Kostman, L J Montaner
The impact of Hepatitis C virus (HCV) RNA levels on immune status in chronically HCV mono-infected when compared to HIV/HCV co-infected on antiretroviral therapy (ART) remains poorly understood. A total of 78 African American subjects HCV viremic/naïve to HCV treatment (33 HCV genotype 1 mono-infected, 45 HCV genotype 1/HIV co-infected on ART) were studied. Clinical and liver enzymes measurements were performed. Whole blood was analyzed for immune subset changes by flow-cytometry. Peripheral blood mononuclear cells (PBMC) were used for same-day constitutive and in vitro Interferon (IFN)-α-induced Signal Transducer and Activator of Transcription (STAT) phosphorylation, K562 target cell lysis and K562 target cell recognition-mediated IFN-γ production...
April 17, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28418984/anger-and-quality-of-life-in-patients-co-infected-with-hiv-and-hepatitis-c-virus-a-cross-sectional-study-anrs-co13-hepavih
#8
Fabienne Marcellin, Camelia Protopopescu, Laure Esterle, Linda Wittkop, Lionel Piroth, Hugues Aumaitre, Olivier Bouchaud, Cécile Goujard, Daniel Vittecoq, François Dabis, Dominique Salmon-Ceron, Bruno Spire, Perrine Roux, Maria P Carrieri
OBJECTIVE: The aim of this study is to document the relationship between anger dimensions (state, trait, expression, and control) and quality of life (QoL) in patients co-infected with HIV and hepatitis C virus (HCV). PATIENTS AND METHODS: This is a cross-sectional study nested in the ANRS CO13-HEPAVIH French national cohort. Anger and QoL were assessed using self-administered questionnaires in 536 HIV-HCV-co-infected patients. Correlations between anger scores (STAXI-2 scale) and QoL scores (WHOQOL-HIV BREF scale) were assessed using Spearman's coefficients...
April 17, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28417245/elbasvir-grazoprevir-a-review-in-chronic-hcv-genotypes-1-and-4
#9
Zaina T Al-Salama, Emma D Deeks
A fixed-dose combination tablet comprising the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) was recently approved for the treatment of chronic HCV genotype 1 and 4 infection in the EU and the USA. In phase III trials, 12 or 16 weeks of treatment with once-daily elbasvir/grazoprevir (fixed-dose tablet or as individual agents), taken with or without ribavirin, generally provided high rates of sustained virological response at 12 weeks (SVR12) in treatment-naive and -experienced adult patients with chronic HCV genotype 1a, 1b or 4 infection, including those with or without compensated cirrhosis, HIV co-infection, inherited blood disorders or chronic kidney disease or patients receiving opioid agonist therapy or of Japanese origin...
April 17, 2017: Drugs
https://www.readbyqxmd.com/read/28416221/ombitasvir-paritaprevir-and-ritonavir-plus-dasabuvir-for-8-weeks-in-previously-untreated-patients-with-hepatitis-c-virus-genotype-1b-infection-without-cirrhosis-garnet-a-single-arm-open-label-phase-3b-trial
#10
Tania M Welzel, Tarik Asselah, Emily O Dumas, Stefan Zeuzem, David Shaw, Rawi Hazzan, Xavier Forns, Tami Pilot-Matias, Wenjing Lu, Daniel E Cohen, Jordan J Feld
BACKGROUND: Clinical studies have shown high rates of sustained virological response (hepatitis C virus [HCV] RNA <15 IU/mL) at post-treatment week 12 (SVR12) in patients with genotype 1b infection with and without cirrhosis who received coformulated ombitasvir, paritaprevir, and ritonavir, plus dasabuvir, without ribavirin, for 12 weeks. In this study, we aimed to assess 8-week treatment with ombitasvir, paritaprevir, and ritonavir, plus dasabuvir, without ribavirin in patients infected with HCV genotype 1b without cirrhosis...
April 13, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28416195/pitavastatin-versus-pravastatin-in-adults-with-hiv-1-infection-and-dyslipidaemia-intrepid-12-week-and-52-week-results-of-a-phase-4-multicentre-randomised-double-blind-superiority-trial
#11
Judith A Aberg, Craig A Sponseller, Douglas J Ward, Vladimir A Kryzhanovski, Stuart E Campbell, Melanie A Thompson
BACKGROUND: People living with HIV-1 infection are at greater risk for cardiovascular disease than seronegative adults. Treatment of dyslipidaemia with statins has been challenging in people with HIV because of an increased potential for drug interactions due to competing cytochrome P450 metabolism between statins and commonly used antiretroviral agents. Neither pitavastatin nor pravastatin depend on cytochrome P450 for primary metabolism. We aimed to assess the safety and efficacy of pitavastatin versus pravastatin in adults with HIV and dyslipidaemia...
April 13, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28413168/prevalence-of-hiv-hbv-and-hcv-and-related-risk-factors-amongst-male-homeless-people-in-lorestan-province-the-west-of-iran
#12
Amin Doosti-Irani, Hamid Mokhaeri, Ali Chegini Sharafi, Mohammad Reza Aghasadeghi, Morteza Hajimiragha, Mohammad Saki, Mohammad Hassan Kayedi, Ehsan Mostafavi
BACKGROUND: Homeless people are at a higher risk of blood-born infectious diseases. The aim of this study was to estimate the prevalence of HIV, HBV, HCV and related risk factors among male homeless people. STUDY DESIGN: A cross-sectional study. METHODS: This study was conducted in Khorramabad City, western Iran from January to June 2015. A pre-designed validated questionnaire was used to collect the data on behavioral and other potential risk factors...
March 11, 2017: Journal of Research in Health Sciences
https://www.readbyqxmd.com/read/28412679/epidemic-characteristics-of-main-infectious-diseases-in-yantai-city-between-2010-and-2012-and-prevention-strategy-research
#13
Huimin Gao, Wenbo Luan, Maobo Wang, Yanjie Dong
To investigate the epidemic characteristics and prevention strategies of main infectious diseases. From 2010 to 2012, 23 notifiable diseases were reported in Yantai with average reported cases of 17,376. The morbidity was the highest in 2012 and the lowest in 2011. The accumulated death toll was 101 with the highest death rate in 2011 and the lowest in 2012. Major class A and B infectious diseases included viral hepatitis, phthisis, syphilis, clap and dysentery. The major class C infectious disease was hand-foot-and-mouth disease every year...
November 2016: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28412290/lack-of-decline-in-hepatitis-c-virus-incidence-among-hiv-positive-men-who-have-sex-with-men-during-1990-2014
#14
Daniela Katinka Van Santen, Jannie Johanna Van Der Helm, Julia Del Amo, Laurence Meyer, Antonella D'arminio Monforte, Matt Price, Charles Antoine Béguelin, Robert Zangerle, Mette Sannes, Kholoud Porter, Ronald Bertus Geskus, Maria Prins
BACKGROUND AND AIMS: Hepatitis C virus (HCV) incidence among HIV-positive men who have sex with men (MSM) has increased since 2000, though regional differences have been documented in recent years. We aimed to 1) estimate trends in HCV incidence among HIV-positive MSM, 2) assess the association between incidence and geographical region, age and HIV-related measurements and, 3) assess temporal changes in time from HIV seroconversion to HCV infection. METHODS: We used data from MSM with well-estimated dates of HIV seroconversion from the CASCADE Collaboration (1990-2014)...
April 12, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28409267/syringe-sharing-among-a-prospective-cohort-of-street-involved-youth-implications-for-needle-distribution-programs
#15
Nikki Bozinoff, Evan Wood, Huiru Dong, Lindsey Richardson, Thomas Kerr, Kora DeBeck
The sharing of previously used syringes is associated with the transmission of Hepatitis C and HIV. This longitudinal study examines syringe borrowing and syringe lending within a prospective cohort of street-involved youth in Vancouver, Canada. From September 2005 to May 2014, data were collected from the At-Risk Youth Study, a cohort of street-involved youth age 14-26 at enrollment, and analyzed using generalized estimating equations. Among 505 participants, 142 (28.1%) reported syringe borrowing and 132 (26...
April 13, 2017: AIDS and Behavior
https://www.readbyqxmd.com/read/28406424/rapid-tests-and-transfusion-safety-in-niamey-niger
#16
Z Mayaki, M Seydou, M Moutschen, A Albert, N Dardenne, D Sondag, D Gossens, C Gérard
To evaluate the virological safety of blood components provided by the Niamey blood transfusion center after undergoing rapid tests. Samples found negative with rapid tests (n = 222) were screened by the Abbott Prism assay. Positive samples were confirmed by appropriate methods. Of 222 samples, nine (4.1%) were reactive for all markers. After confirmation, seven samples were positive (i.e., 3.2% false-negative results) : five (2.3%) for the surface antigen of hepatitis B (HBsAg) and two (0.9%) for the antibody directed against the hepatitis C virus (HCV-Ab)...
February 1, 2017: Médecine et Santé Tropicales
https://www.readbyqxmd.com/read/28404202/hepatitis-c-treatment-as-prevention-evidence-feasibility-and-challenges
#17
REVIEW
Behzad Hajarizadeh, Jason Grebely, Marianne Martinello, Gail V Matthews, Andrew R Lloyd, Gregory J Dore
The advent of interferon-free direct-acting antiviral therapy for hepatitis C virus (HCV) infection has heightened discussion of treatment as prevention. Rapid scale-up in many settings, and the prospect of further treatment simplification have extended therapeutic optimism towards HCV elimination. However, questions remain regarding the feasability of HCV treatment as prevention, including real world efficacy of direct-acting antiviral therapy, particularly among people who inject drugs, and whether expanded treatment access will be sufficient to reduce HCV transmission...
December 2016: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28404136/non-alcoholic-fatty-liver-disease-and-non-alcoholic-steatohepatitis-in-patients-with-hiv
#18
REVIEW
Elizabeth C Verna
Liver disease is a leading cause of morbidity and mortality among people with HIV, and in this era of safer and more effective hepatitis C therapy, non-alcoholic fatty liver disease (NAFLD) could soon emerge as the most common liver disease in this population. NAFLD is common among patients with HIV, and might be more likely to progress to non-alcoholic steatohepatitis (NASH) and NAFLD-related fibrosis or cirrhosis in these patients than in individuals without HIV. Several mechanisms of NAFLD pathogenesis are postulated to explain the disease severity in patients with HIV; these mechanisms include the influence of the gut microbiome, and also metabolic, genetic, and immunological factors...
March 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28404135/incidence-risk-factors-and-prevention-of-hepatitis-c-reinfection-a-population-based-cohort-study
#19
Nazrul Islam, Mel Krajden, Jean Shoveller, Paul Gustafson, Mark Gilbert, Jane A Buxton, Jason Wong, Mark W Tyndall, Naveed Zafar Janjua
BACKGROUND: People remain at risk of reinfection with hepatitis C virus (HCV), even after clearance of the primary infection. We identified factors associated with HCV reinfection risk in a large population-based cohort study in British Columbia, Canada, and examined the association of opioid substitution therapy and mental health counselling with reinfection. METHODS: We obtained data from the British Columbia Hepatitis Testers Cohort, which includes all individuals tested for HCV or HIV at the British Columbia Centre for Disease Control Public Health Laboratory during 1990-2013 (when data were available)...
March 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28403051/modelling-cd4-t-cell-recovery-in-hepatitis-c-and-hiv-co-infected-children-receiving-antiretroviral-therapy
#20
Adedeji O Majekodunmi, Claire Thorne, Ruslan Malyuta, Alla Volokha, Robin E Callard, Nigel J Klein, Joanna Lewis
BACKGROUND: The effect of hepatitis C virus (HCV) coinfection on CD4 T cell recovery in treated HIV-infected children is poorly understood. OBJECTIVE: To compare CD4 T cell recovery in HIV/HCV coinfected children with recovery in HIV monoinfected children. METHOD: We studied 355 HIV monoinfected and 46 HIV/HCV coinfected children receiving antiretroviral therapy (ART) during a median follow-up period of 4.2 years (interquartile range: 2.7-5...
May 2017: Pediatric Infectious Disease Journal
keyword
keyword
8632
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"